9702585-2

RTMP's copy

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 5/06, C07D 207/16, A61K 38/05, 31/40 // C07K 7/22 — A1

(11) International Publication Number: WO 96/18643

(43) International Publication Date: 20 June 1996 (20.06.96)

(21) International Application Number: PCT/EP95/04910

(22) International Filing Date: 12 December 1995 (12.12.95)

(30) Priority Data:
9425085.9 13 December 1994 (13.12.94) GB
9426016.3 22 December 1994 (22.12.94) GB

(71) Applicant *(for all designated States except AT DE GB US)*: SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH).

(71) Applicant *(for DE only)*: SANDOZ-PATENT-GMBH [DE/DE]; Humboldtstrasse 3, D-79539 Lörrach (DE).

(71) Applicant *(for AT only)*: SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).


(71) Applicant *(for GB only)*: SANDOZ PHARMACEUTICALS (UK) LTD. [GB/GB]; Calverley Lane, Horsforth, Leeds LS18 4RP (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KO, Soo, Young [KR/GB]; Flat 5, 42 Belsize Park Gardens, London NW3 4LY (GB). WALPOLE, Christopher [GB/GB]; 8 Fassett Road, Hackney, London E8 1PA (GB).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

**Published**
*With international search report.*
*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: TACHYKININ ANTAGONISTS




(I)

(57) Abstract

Compounds of formula (I), wherein $R_1$ is mono- or di-substituted phenyl, n is zero or 1, $X_1$ is oxygen, sulfur or =NCN, $X_2$ and $X_3$ are oxygen or sulfur, $R_2$ is hydrogen or methyl, $R_3$ is phenyl, halo-substituted phenyl, 2-naphthyl, IH-indol-3-yl or 1-methyl-indol-3-yl, Z is $-N(CH_3)-$ or $-CH_2-$, $R_4$ is phenyl, 3,5-bis(trifluoromethyl)phenyl or pyridyl and $R_5$ is hydrogen, phenyl 3,5-bis(trifluoromethyl)phenyl or pyridyl, whereby, when $X_3$ is sulfur, Z is $-N(CH_3)-$ and acid addition salt thereof have tachykinin antagonist activity and are useful as pharmaceuticals, e.g. for the treatment of pain.